Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a $37 price target. This reaffirms the firm's positive outlook on ACADIA's stock.
May 09, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on ACADIA Pharmaceuticals with a $37 price target, indicating a positive outlook.
The reiteration of an Overweight rating and a $37 price target by a reputable analyst like Charles Duncan from Cantor Fitzgerald is likely to instill confidence among investors and could lead to a positive short-term price movement for ACADIA Pharmaceuticals. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100